Abrdn PLC Harmony Biosciences Holdings, Inc. Transaction History

Abrdn PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$28.81 - $33.01 $6.12 Million - $7.01 Million	-212,438 Reduced 41.8%	295,811 $8.92 Million
Q1 2024 May 08, 2024	SELL	$29.93 - $35.06 $746,454 - $874,396	-24,940 Reduced 4.68%	508,249 $17.1 Million
Q4 2023 Jan 31, 2024	SELL	$19.2 - $33.78 $930,336 - $1.64 Million	-48,455 Reduced 8.33%	533,189 $17.2 Million
Q3 2023 Nov 06, 2023	SELL	$31.89 - $39.03 $2 Million - $2.44 Million	-62,604 Reduced 9.72%	581,644 $19.1 Million
Q2 2023 Jun 20, 2024	BUY	$30.5 - $37.4 $444,934 - $545,591	14,588 Added 2.32%	644,248 $22.7 Million
Q2 2023 Aug 04, 2023	BUY	$30.5 - $37.4 $444,934 - $545,591	14,588 Added 2.32%	644,248 $22.7 Million
Q1 2023 Jun 20, 2024	SELL	$30.8 - $53.92 $1.88 Million - $3.29 Million	-61,074 Reduced 8.84%	629,660 $20.6 Million
Q1 2023 Apr 28, 2023	SELL	$30.8 - $53.92 $1.88 Million - $3.29 Million	-61,074 Reduced 8.84%	629,660 $20.6 Million
Q4 2022 Jun 20, 2024	BUY	$45.4 - $60.91 $8.28 Million - $11.1 Million	182,485 Added 35.9%	690,734 $38.1 Million
Q4 2022 Feb 09, 2023	BUY	$45.4 - $60.91 $31.4 Million - $42.1 Million	690,734 New	690,734 $38.1 Million

243

45.2M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.04B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

Stay updated on Abrdn PLC with notifications on news.